期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

TGF-β信号通路与造血系统肿瘤 被引量：3

TGF-β signaling and hematopoietic malignancies
暂未订购
导出
摘要 转化生长因子β(TGF-β)是造血细胞生长的负调控因子,TGF-β/SMAD信号途径在造血系统恶性肿瘤的发生中起到重要的作用,TGF-β表达及受体或受体后水平缺陷都可导致造血细胞的恶性增殖。深入研究该信号通路对于探寻造血系统恶性肿瘤的发病机制及开发以该通路环节为靶点的靶向治疗具有积极意义。 Transforming growth factor β （TGF-β） is a negative regulated cytokine for growth of hematopoieticcells. TGF-β/SMAD signaling pathway plays an important part in pathogenesis of hematopoietic malignance diseases. The deficiencies of TGF-β expression and mutations of TGF-β receptors or downstream signaling pathways can cause malignant proliferation of hematopoietic cells. To study the signaling pathway of TGF-13 may attribute to the recognize of the pathogenesis of hematopoietic malignances and the development of therapy targeting at the TGF-β pathway.
作者 王敏 王立茹
机构地区 首都医科大学附属复兴医院血液内科
出处 《基础医学与临床》 CSCD 北大核心 2014年第3期426-429,共4页 Basic and Clinical Medicine
基金 北京市优秀人才培养项目(20071D0900700341) 首都医学发展科研基金(2009-3192)
关键词 转化生长因子Β 信号通路 造血系统 肿瘤 TGF-β signaling hematopoietic malignance
分类号 R733 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Khin SS,Kitazawa R,Kondo T. Epigenetic alteration by DNA promoter hypermethylation of genes related to transforming growth factor-β (TGF-β) signaling in cancer[J].Cancers,2011.982-993.
  • 2Runyan CE,Hayashida T,Hubchak S. Role of SARA (SMAD anchor for receptor activation) in maintenance of epithelial cell phenotype[J].Journal of Biological Chemistry,2009.25181-25189.
  • 3Wu Y,Chen P,Huang HF. Reduction of transforming growth factor-β1 expression in leukemia and its possible role in leukemia development[J].Leukemia & lymphoma,2012.145-151.
  • 4凡治国,张连生,柴晔,曾鹏云,吴重阳.Th17细胞水平的变化与急性髓系白血病发病关系的探讨[J].中华血液学杂志,2010,31(9):617-620. 被引量：22
  • 5Szczepanski MJ,Szajnik M,Czystowska M. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia[J].Clinical Cancer Research,2009.3325-3332.
  • 6Szczepanski MJ,Szajnik M,Welsh A. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1[J].HAEMATOLOGICA,2011.1302-1309.
  • 7Sung JY,Kim H,Kim YN. Interferon consensus sequence binding protein-induced cell proliferation is mediated by TGF-β signaling and p38 MAPK activation[J].Laboratory Investigation,2011.1304-1313.
  • 8Hager M,Pedersen CC,Larsen MT. MicroRNA-130a-mediated down-regulation of Smad4 contributes to reduced sensitivity to TGF-β1 stimulation in granulocytic precursors[J].Blood,2011.6649-6659.
  • 9Arai S,Yoshimi A,Shimabe M. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells[J].Blood,2011.6304-6314.
  • 10Quéré R,Karlsson G,Hertwig F. Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation[J].Blood,2011.5918-5930.

二级参考文献11

  • 1Veldhoen M,Hocking RJ,Atkins CJ,et al.TGF-β in the context of an inflammatory cytokine milieu supports denovo differentiation of IL-17-producing T cells.Immunity,2006,24:179-189.
  • 2Bettlli E,Carrier Y,Gao W,et al.Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.Nature,2006,441:235-238.
  • 3Beyer M,Schultze JL.Regulatory T cells in cancer.Blood,2006,108:804-811.
  • 4Wang X,Zheng J,Liu J,et al.Increased population of CD4^+ CD25^+ regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients.Eur J Haematol,2005,75:468-476.
  • 5Harrington LE,Hatton RD,Mangan PR,et al.lnterleukin 17-producing CD4^+ efector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.Nat Immunol,2005,6:1123-1132.
  • 6Bettelli E,Korn T,Kuchroo VK.Th17:the third member of the effector T cell trilogy.Curr Opin Immuno1,2007,19:1-6.
  • 7Manel N,Unutmaz D,Littman DR.The differentiation of human Th17 cells requires trans forming growth factor-beta and induction of the nuclear receptor RORgammat.Nat Immunol,2008,9:641-649.
  • 8Numasaki M,Watanabe M,Suzuki T,et al.IL-17 enhances the net aagiogenic activity and in vivo growth of human non-small cell lung cancer in SCD mice through promoting CXCR-2-dependent angiogenesis.lmmunol,2005,175:6177-6189.
  • 9Zhang B,Rong G,Wei H,et al.The prevalence of Th17 cells in patients with gastric cancer.Bioehem Biophys Res Commun,2008,374:533-537.
  • 10Gogas H,Ioannovich J,Dafni U,et al.Prognostic significance of autoimmunity during treatment of melanoma with interferon.N Engl J Med,2006,354:709-718.

共引文献21

同被引文献19

  • 1Yi Ru, Qinhao Wang, Xiping Liu, et al. The Chimeric Ubiquitin Ligase SH2-U-box Inhibits the Growth of Imatinib-sensitive and Resistant CML by Targeting the Native and T315I-mutant BCR-ABL [ J]. Sci Rep, 2016,107(7) : 1029-1038.
  • 2Parker WT, Ho M, Scott HS, et al. Poor Response to Second-line Ki- nase Inhibitors in Chronic Myeloid Leukemia Patients with Multiple Lew-level Mutations, Irrespective of Their Resistance Profile [ J ]. Blood ,2012,119 (10) :2234-2238.
  • 3Peng B, Hayes M, Resta D ,et al. Pharmacokineties and Pharmaeody- namics of Imatinib in a Phase I Trial with Chronic Myeloid Leukemia Patients[ J]. J Clin Oncol,2004,22 (5) :935-942.
  • 4Larson RA, Druker B J, Guilhot F, et al. Imatinib Pharmaeokineties and Its Correlation with Response and Safety in Chronic-phase Chronic Myeloid Leukemia: a Subanalysis of the IRIS Study[ J]. Blood,2008, 111 (8) :4022-4028.
  • 5Apperley JF. Part I:Meehanisms of Resistance to Imatinib in Chronic Myeloid Leukaemia[ J]. Lancet Oncol,2007, 8 ( 11 ) : 1018-1029.
  • 6Ernst T, Hoehhaus A. Chronic Myeloid Leukemia:Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated with Disease Pro- gression[ J]. Semin Oncol, 2012,39( 1 ) :58-66.
  • 7Benjamin Hanfstein, Martin C. Muller, Sebastian Kreil,et al. Dynamics of Mutant BCR-ABL -positive Clones after Cessation of Tyrosine Ki- nase Inhibitor Therapy[J]. Haematologica,2011,96(3) :360-366.
  • 8Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Phila- delphia-positive Patients The GIMEMA Working Party on Chronic My- eloid Leukemia[ J]. Clin Cancer Res,2006,12(24) :7374-7379.
  • 9Shibuta T, Honda E, Shiotsu H, et al. Imatinib Induces Demethylation of miR-203 Gene: an Epigenetic Mechanism of Anti-tumor Effect of Imatinib[ J]. Leuk Res,2013,37 (10) :1278-1286.
  • 10Mosakhani N, Mustjoki S, Knuutila S. Down-regulation of miR-181 c in Imatinib-resistant Chronic Myeloid Leukemia [ J ]. Mol Cytogenet, 2013,6 ( 1 ) :27.

引证文献3

二级引证文献9

基础医学与临床
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部